Irvalec® ( PM 02734 ) .... Gastroesophageal (GE) cancer is the 2nd leading cause of cancer-related deaths. Despite recent advances, no standard options are available once pts fail first-line combination chemotherapy regimens. Elisidepsin has shown promising activity in unselected pretreated GE pts in phase I, including 1 complete response and 2 prolonged disease stabilizations of around 12 months each.
...